TGF-β has thus become a promising target in cancer therapy, and treatments targeting the TGF-β pathway, such as neutralizing antibodies and soluble TGF-β receptors, have been evaluated in preclinical tests and even clinical trials [18]. This evidence concerns the gene TGFB1 and cancer.